Int. J. Mol. Sci. 2012, 13(5), 5519-5527; doi:10.3390/ijms13055519
Article

Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization

1 Department of General Surgery, General Hospital of Shenyang Military Area Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110840, China 2 Division of Nephrology, Guangdong Provincial Institute of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 10 April 2012; in revised form: 26 April 2012 / Accepted: 27 April 2012 / Published: 8 May 2012
(This article belongs to the Special Issue Advances in Molecular Oncology)
PDF Full-text Download PDF Full-Text [195 KB, Updated Version, uploaded 10 May 2012 15:57 CEST]
The original version is still available [195 KB, uploaded 8 May 2012 10:26 CEST]
Abstract: Fluorescence in situ hybridization (FISH) assay is considered the “gold standard” in evaluating HER2/neu (HER2) gene status. However, FISH detection is costly and time consuming. Thus, we established nuclei microarray with extracted intact nuclei from paraffin embedded breast cancer tissues for FISH detection. The nuclei microarray FISH (NMFISH) technology serves as a useful platform for analyzing HER2 gene/chromosome 17 centromere ratio. We examined HER2 gene status in 152 cases of invasive ductal carcinomas of the breast that were resected surgically with FISH and NMFISH. HER2 gene amplification status was classified according to the guidelines of the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP). Comparison of the cut-off values for HER2/chromosome 17 centromere copy number ratio obtained by NMFISH and FISH showed that there was almost perfect agreement between the two methods (κ coefficient 0.920). The results of the two methods were almost consistent for the evaluation of HER2 gene counts. The present study proved that NMFISH is comparable with FISH for evaluating HER2 gene status. The use of nuclei microarray technology is highly efficient, time and reagent conserving and inexpensive.
Keywords: breast cancer; microarray; nuclei microarray; fluorescence in situ hybridization (FISH); HER2 gene

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Jiang, H.; Bai, X.; Zhang, C.; Zhang, X. Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization. Int. J. Mol. Sci. 2012, 13, 5519-5527.

AMA Style

Jiang H, Bai X, Zhang C, Zhang X. Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization. International Journal of Molecular Sciences. 2012; 13(5):5519-5527.

Chicago/Turabian Style

Jiang, Huiyong; Bai, Xiaoyan; Zhang, Cheng; Zhang, Xuefeng. 2012. "Evaluation of HER2 Gene Amplification in Breast Cancer Using Nuclei Microarray in Situ Hybridization." Int. J. Mol. Sci. 13, no. 5: 5519-5527.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert